KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 158 filers reported holding KARYOPHARM THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.47 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,072 | -25.1% | 800 | 0.0% | 0.00% | – |
| Q2 2023 | $1,432 | +47633.3% | 800 | -7.0% | 0.00% | – |
| Q1 2023 | $3 | 0.0% | 860 | +7.5% | 0.00% | – |
| Q4 2022 | $3 | -100.0% | 800 | -86.0% | 0.00% | – |
| Q3 2022 | $26,000 | +550.0% | 5,700 | +612.5% | 0.00% | – |
| Q2 2022 | $4,000 | -33.3% | 800 | 0.0% | 0.00% | – |
| Q1 2022 | $6,000 | -14.3% | 800 | 0.0% | 0.00% | – |
| Q4 2021 | $7,000 | +40.0% | 800 | 0.0% | 0.00% | – |
| Q3 2021 | $5,000 | -37.5% | 800 | 0.0% | 0.00% | – |
| Q2 2021 | $8,000 | -81.4% | 800 | -80.2% | 0.00% | – |
| Q1 2021 | $43,000 | -31.7% | 4,050 | 0.0% | 0.00% | – |
| Q4 2020 | $63,000 | +23.5% | 4,050 | +15.7% | 0.00% | – |
| Q3 2020 | $51,000 | +218.8% | 3,500 | +311.8% | 0.00% | – |
| Q2 2020 | $16,000 | +45.5% | 850 | +44.1% | 0.00% | – |
| Q1 2020 | $11,000 | – | 590 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 3,561,052 | $26,245,000 | 5.86% |
| Palo Alto Investors LP | 5,621,533 | $41,431,000 | 3.20% |
| Iron Triangle Partners LP | 2,000,000 | $14,740,000 | 1.75% |
| Altium Capital Management LP | 645,000 | $4,754,000 | 1.59% |
| Birchview Capital, LP | 269,332 | $1,985,000 | 1.43% |
| Rubric Capital Management LP | 3,607,443 | $26,587,000 | 0.96% |
| Lombard Odier Asset Management (Switzerland) SA | 776,053 | $5,720,000 | 0.45% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,344,929 | $9,912,000 | 0.40% |
| Golden State Equity Partners | 41,850 | $308,000 | 0.16% |
| Hennion & Walsh Asset Management, Inc. | 385,837 | $2,844,000 | 0.15% |